Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (January 2015)
34 slides from Fluoropharma Medical's investor presentation, Jan 13, 2015
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics. (OTCQB:FPMI)
Slide 2: Forward-Looking Statements
Fluoro — Forward-Looking Statements Pharma This presentation contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered
Slide 3: Patients will die of heart disease
Patients will die of heart disease Acardiac perfusion scan is performed Portfolio of compounds in heart disease BFPET CardioPET ——_—VasoPET www. FluoroPharma.com
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Fluoro — Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT + Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital + Next generation molecular imaging drugs for diagno
Slide 5: Cardiovascular Disease is a Major Global Health Burden
Cardiovascular Disease is a Major Global Health Burden: Fluoro — Pharma ath ERK KEY FACTS —- US AND WW WHO: “Neglected Global Epidemic" + 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. + 4/3 of deaths in China, ¥% in Europe + 2.4M deaths US: top cause (38.5%) KEY UNMET N
Slide 6: Patients With Known or Suspected CAD: Decision Tree
Patients With Known or Suspected CAD: Decision Tree Pharma Stress Imaging + Viability Imaging + Stress induced ischemia + Hibernation LV function More aggressive Less aggressive www. FluoroPharma.com Adapted from Bax W et al. Heart. 2004;90(Suppl V):v26-v33.
Slide 7: Molecular Imaging Allows Visualization of the Heart
Molecular Imaging Allows isualization of the Heart yaww.FluoroPharma.com
Slide 8: luoro. ——
luoro. —— _— Pharma yaww.FluoroPharma.com
Slide 9: FluoroPharma Medical Inc. Development Portfolio
FluoroPharma Medical Inc. Development Portfolio For use in combination with stress-testing in patients with presumptive chronic CAD To replace SPECT in institutions with PET capability Phase 1 (US) Phase 2 (US) US. patent through 2025 Perfusion images n potential patients | For diagnosis of acute an
Slide 10: Coronary Artery Disease Treatment Flow Model
Coronary Artery Disease Treatment Flow Model Pharma Origination Upciagnosed CAD Patio =20uM |” stoec rai heat aack ‘General Fay / Oto Phskisn ype inenisy Gane Cardlogit Prtet proba of CAD oe) —eeen) ieemees) x * lor Hospital * Hospital Outpatient += Hospital inpatiant Trees Sree Sect) Pet HighRisk S
Slide 11: BFPET Should Provide Superior Performance in Both PPV and NPV
BFPET Should Provide Superior Performance in Both PPV and NPV: As shown below, BFPET images have higher resolution than market-standard SPECT on a qualitative basis. ‘Tc-99m Sestamibi Standard of ce | | BFPET On SPECT this patient appeared to ..-while BFPET clearly showed that have a defect... this
Slide 12: BFPET Clinical Use
BFPET Clinical Use — Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (e.g. MIBI, tetrofosmin, T-204) or PET (Rb-82)
Slide 13: BFPET Images Heart Disease at Higher Resolution
BFPET Images Heart Disease at Higher Resolution BFPET’s extremely high resolution allows the cardiologist to differentiate among ischemic, infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis. Tc-99m Sestamibi in
Slide 14: BFPET Phase Study
BFPET Phase 1 Study Pharma ‘Source: Investigator Initiated Trial; PLA 301, Beijing, China. Images courtesy of Dr. Tien yaww.FluoroPharma.com
Slide 15: The BFPET Opportunity: United States
The BFPET Opportunity: United States — Pharma As: iption Est. PET Market Market Procedures Size Myocardial perfusion imaging 22 Million 5.0 million 60 Projected BFPET Scans Luis 50 40 20 20 10 year’ EE 459 Projected BFPET Revenue 404 S-BILLIONS, ear Years Yer www. FluoroPharma.com 15, ‘Souree: Black
Slide 16: Cost Effectiveness Will Drive Referrals and Reimbursement to Cardiac PET
Cost Effectiveness Will Drive Referrals and Reimbursement to Cardiac PET Fluoro = Drivers and Benefits: @ sxension of ivieaieicatons/stnicat needs lever rsleion cose Improved diagnosis accuracy Improved patient outcomes Core er Fuslon of enamel and turconal studies ‘Superior image quality Improved q
Slide 17: Physicians across the US and EU have expressed a very strong willingness to utilize BFPET
Physicians across the US and EU have expressed a Fluoro — very strong willingness to utilize BFPET once it is approved Pharma inded research, the product profile for BFPET gained very positive responses from specialists where indicated willing to increase estimates use after more comfort. a 8 @ surv
Slide 18: Fatty Acid Metabolism is at the Intersection of Diabetes and Heart Failure
Fatty Acid Metabolism is at the Intersection of Diabetes and Heart Fail Pharma == | paired FA oxidation MELLITUS w= S www. FluoroPharma.com
Slide 19: Heart Failure is Reaching Epidemic Proportions
Heart Failure is Reaching Epidemic Proportions: ~70% of HF is driven by ischemic heart disease The average life expectancy after HF diagnosis is 8 years, 50% die within 5 HF prevalence is expected to increase 46% from 2012 to 2030 There are 825,000 new cases of HF annually in the US alone Total cost
Slide 20: FCPHA (CardioPET) Results
FCPHA (CardioPET) Results — Pharma Normal CAD Subject Fatty acid analog that detects regions of metabolic insufficiency PHASE | TRIAL COMPLETED (15 NHV and 6 CAD patients) =» * CardioPET promising safety with no AEs detected * Clinical findings consistent with MPI SPECT Infaroted region of the heart
Slide 21: Phase II CardioPET Data is Starting to Be Presented
Phase || CardioPET Data is Starting to Be Presented ‘SAFETY, IMAGE QUALITY AND OPTIMAL TIMING FOR MYOCARDIAL IMAGING USING THE F-18 FATTY ACID ANALOG CarDioPET IN KNOWN OR SUSPECTED CAD PATIENTS Damar Cargo, 0 Vnraot A Pango I ee, CardioPET PHASE Il STUDY Results: image qualityoptimal timing nk quay
Slide 22: SNMMI Poster on CardioPET Quantitation (1/2)
SNMMI Poster on CardioPET Quantitation (1/2) O.Gheysens), A. Postnov 1. Muyts?X Van tere Sans 53M. Cerqueea™ Pharma 5 uz Quantification of myocardial perfusion in humans by PET/CT ay LEUVEN and the fatty acid analogue #®F-FCPHA: a feasibility study LEUVEN : Objective: The “F-labeled fatty acid, tran
Slide 23: SNMMI Poster on CardioPET Quantitation (2/2)
SNMMI Poster on CardioPET Quantitation (2/2) Fluoro = Pharma ‘one compartment we parameter mode Input id trinestaty ones, | stane MEFCPHA images tom 2:8 minutes were tf srt | erpored wih comespondng mre SECT oe = {fags sueee FCA ages aly ered a | person éectin the some sor or SPECT ages fu | Ste sey
Slide 24: Preliminary Imaging Performance: PET vs. SPECT
Preliminary Imaging Performance: PET vs. SPECT Pharma IMAGES THAT TEACH A new F-18 labeled PET tracer for fatty acid imaging oct MO." * CardioPET images revealed alterations of fatty acid uptake in regions without abnormalities on Te-99m sestamibi SPECT * Fatty acid uptake and retention may be bette
Slide 25: CardioPET Clinical Use
CardioPET Clinical Use — Pharma DIAGNOSIS OF CAD AT REST Evaluate CAD in patients that cannot exercise CARDIAC VIABILITY ASSESSMENT Identify patients that may benefit from PCI or revascularization and guide intervention CURRENT TREATMENT Invasive coronary angiography and PCI CON eAE NEED 1.3 million
Slide 26: CardioPET may provide a critical direction in a diagnosis of exclusion
CardioPET may provide a critical direction in a diagnosis of exclusion ~ Pharma Physicians indicate they would employ CardioPET when a patient presents with an equivocal ACS—typically, when the patient has a “strong story’ of chest pain and shortness of breath but shows up as negative on initial tes
Slide 27: The CardioPET Opportunity
The CardioPET Opportuni Commercial Assumptions | Est. PET Market Market Procedures Procedures CAD diagnosis at rest 3.8 million 380 million Cardiac viability peti 46 ™million 0S milion Myocardial perfusion imaging Az inition Ce smillions Courtesy of Fabian Demeure, UCL, Belgium Projected CardioPET S
Slide 28: CardioPET (18-F FCPHA)
CardioPET 18-F FCPHA) PET/CT Fusion on Modern Scanners Provide Anatomy and Function Pharma infer yaww.FluoroPharma.com
Slide 29: Why PET, and Why Now
Why PET, and Why Now: Distribution, infrastructure and increasing installed base Pharma + New care models are driving cost efficiency and outcomes improvement + PET has a significantly higher rate of specificity and sensitivity than SPECT + Provides a more accurate diagnosis for patients, potentiall
Slide 30: Substantial Installed Base in the US
Substantial Installed Base in the US ~2800 Scanners Operating at ~40% Capacity — Pharma Cardiac stress tests are already performed more than 60% of the time at centers with PET machines. ‘The PET machines are currently imaging oncology patients for 95% of their workload Distribution of PET Machines
Slide 31: Production of Finished Material
Production of Finished Material: The US Has an Established Cyclotron Distribution Network Approximately 100 FDG production sites (Cardinal Health, IBA, PETNET) will allow FluoroPharma to provide a high level of customer service, enabling product delivery within two to three hours to 85% of PET insti
Slide 32: Experienced Management Team and Advisors
Fluoro — Experienced Management Team and Advisors Pharma H Willam Strauss, MD Daniel Berman. MD Peter Conth MO, PRO lazer Edelman, MD, PRD. Heiich Schelbert. MD Thijs Spoor President. CEO + Healthcare executive wth >15 years medical industiy experience + Former securties analyst at | P Morgan and Gr
Slide 33: Investment Highlights
Investment Highlights = Pharma Radiopharmaceutical company with two next generation cardiovascular perfusion imaging agents in Phase 2 ‘+ Short Study Timelines/regulatory pathway + Available data already demonstrates better imaging characteristics than traditional SPECT + Established reimbursement a
Slide 34: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics. (OTCQB:FPMI)
FluoroPharma Medical — Investor Presentation (January 2015) on 6ix